Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Kosan Biosciences  (Stock symbol: KOSN ) Acquired by Bristol-Myers Squibb (2008 $ 190,000,000)

3832 Bay Center Place
Hayward, CA 94545
Website Company Summary Management Team

Outside board: (May no longer be on the board) Kevan Clemens (Hoffmann-La Roche EVP Business Development) Bruce Chabner (Massachusetts General Hospital) Peter Davis (Pulsar International) Jean Deleage (Alta Partners) Charles J Homcy (Millennium Pharmaceuticals) Chaitan Khosla (Stanford University Professor) Christopher T Walsh (Harvard Medical School)

Business description: Kosan uses its proprietary technologies to develop drug candidates from an important class of natural product compounds known as polyketides. Polyketides are a rich source of many pharmaceuticals, including antibiotics (e.g., Zithromax, Biaxin, erythromycin and tetracyclines), anticancer drugs (e.g., doxorubicin), cholesterol-lowering drugs (e.g., Zocor, Mevacor and Pravachol), immunosuppressants (e.g., FK506 and rapamycin) and other therapeutics. However, polyketides are made in very small amounts in microorganisms and are difficult to make or modify chemically. Kosan's technologies enable the creation, modification and production of polyketides in ways that are not otherwise possible. Kosan can introduce specific alterations in the structure of known polyketides in order to improve on existing drugs and to rapidly create novel polyketides as potential new drugs. We also can take the genetic instructions for making a polyketide out of one microorganism and put them into another microorganism that provides a more favorable environment to grow and produce more of the polyketides.
Customers include: Pfizer
Partners include: ChironRoche

Rounds: 4
Capital raised: 24.3M
Ownership: Acquired by Bristol-Myers Squibb (2008 $ 190,000,000)
Stock Symbol: KOSN
Corporate investors: Chiron

Last Tweets


Last Mentions

Record updated: May 2008
Sector: Biotech
Year Founded: 1995
Headcount: 51-75 as of Mar 2008
Rounds: 4
Capital Raised: 24.3M
Ownership: Acquired by Bristol-Myers Squibb (2008 $ 190,000,000)
Stock Symbol: KOSN